References
- Minoda M, Hamada K, Higashikawa M, Sugishima H, Funauchi M, Horiuchi A. Examination of the inhibitory effects of interferon-gamma on interleukin-4-induced stimulation of resting B cells from NZB/NZW F1 mice. Clin exp Immunol 1989; 78: 115–119
- Hang L, Izui S, Dixon FJ. (NZW x BXSB)F1 Hybrid. A model of acute lupus and coronary vascular disease with myocardial infarction. J Exp Med 1981; 154: 216–221
- Oyaizu N, Yasumizu R, Miyama-lnaba M, Nomura S, Yoshida H, Miyawaki S. (NZW x BXSB)F1 mouse. A new animal model of idiopathic thrombocytopenic purpura. J Exp Med 1988; 167: 2017–2022
- Hang L, Stephens-Larson P, Henry JP, Dixon FJ. The role of hypertension in the vascular disease and myocardinal infarcts associated with murine systemic lupus erythematosus. Arthritis and Rheumatism 1983; 26: 1340–1345
- Birkeland LM, Johnson P, Trowbridge IS, Pure E. Changes in CD45 isoform expression accompany antigen-induced murine T-cell activation. Proc Natl Acad Sci 1989; 86: 6734–6743
- Boom WH, Liano D, Abbas AK. Heterogeneity of helper/inducer T lymphocytes. Effects of interleukin 4-and inter-leukin 2-producing T cell clones on resting B lymphocytes. J Exp Med 1988; 167: 1350–1363
- Inaba M, Inaba K, Adachi Y, Nango K, Ogata H, Muramatsu S. Functional analyses of thymic CD5+ B cells. Responsiveness to major histocompatibility complex class II-restricted T blasts but not to lipopolysaccharide or anti-IgM plus interleukin 4. J Exp Med 1990; 171: 321–326
- Ikehara S, Good RA, Nakamura T, Sekita K-I, Inoue S, Maung Maung Oo. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci 1985; 82: 2483–2487
- Theofilopoulos AN, Dixon FJ. Experimental murine systemic lupus erythematosus. Systemic lupus erythematosus 1987; 121–202
- Hardy RR, Hayakawa K. Development and physiology of Ly-1 B and its human homologue, Leu-1 B. Immunol Rev 1986; 93: 53–80
- Ying-zi C, Rabin E, Wortis HH. Treatment of murine CD5-B cells with anti-Ig, but not LPS, induce surface CD5: two B-cell activation pathways. Int Immunol 1991; 3: 467–476
- Ovnic M, Corley RB. Quantitation of cell surface molecules on a differentiating, Ly-1+ B cell lymphoma. J Immunol 1987; 138: 3075–3082
- Gignac SM, Buschle M, Hoffbrand AV. Down regulation of CD5 mRNA in B-chronic lymphocytic leukemia cells by differentiation-inducing agents. Eur J Immunol 1990; 20: 1119–1123
- Ikehara S, Yasumizu R, Inaba M, Izui S, Hayakawa K, Sekita K. Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogenic bone marrow transplantation. Proc Natl Acad Sci 1989; 86: 3306–3310
- Ikehara S, Inaba M, Ishida T, Ogata H, Hisha H, Yasumizu R, Champlin RE, Gale RP. Rationale for transplantation of both allogenic bone marrow and stromal cells in the treatment of autoimmune diseases. New strategies in bone marrow transplantation. Wiley Liss, New York 1991; 251–257
- Ikehara S, Kawamura M, Takao F, Inaba M, Yasumizu R, Soe Than. Organ-specific and systemic autoimmune diseases originated from defects in hematopoietic stem cells. Proc Natl Acad Sci 1990; 87: 8341–8344